Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients

Table 1 Distribution of most advanced findings on colonoscopy

Most advanced finding	n (%)
Colorectal cancer	4 (8.2)
Advanced adenoma1	21 (42.9)
Non advanced adenoma2	15 (30.6)
1-2 adenomas, > 5 and < 10 mm	7
> 3 adenomas, any size < 10 mm	5
1-2 adenomas, ≤ 5 mm	3
No colorectal neoplasia	9 (18.4)
HP only	5
No findings	4
Total Patients	49 (100)

¹Includes adenoma with high grade dysplasia, villous adenoma, tubulovillous adenoma and tubular adenoma and sessile serrated adenoma/polyp ≥ 10 mm;

²Non advanced adenoma includes tubular adenomas < 10 mm with no advanced features. HP: Hyperplastic polyp.

Table 2 Features of the advanced colorectal neoplasms found in Cologuard positive patients on colonoscopy

Index lesion	Greatest dimension (mm)					Proximal colon
	10	11-19	20-29	30+	Total
CRC1	0	1	2	1	4	75% (3/4)
HGD	0	0	1	0	1	0% (0/1)
TVA/VA2	1	3	4	1	9	38% (3/8)
TA	3	6	0	1	10	40% (4/10)
SSA/P	1	0	0	0	1	100% (1/1)
Total	4	10	7	3	24	40% (8/20)

Index lesion only.

¹Stage I (2), Stage II (2);

²1 location not reported. Index lesion: Most clinically significant lesion found on colonoscopy; CRC: Colorectal cancer; HGD: High grade dysplasia; TVA/VA: Tubulovillous adenoma/villous adenoma; TA: Tubular adenoma ≥ 10 mm with no HGD or villous features; SSA/P: Sessile serrated adenoma/polyp ≥ 10 mm.